Medical Devices

John Crowley, who fought to save his own children, will now shape the future of medicine as he headlines the landmark 2026 MDA conference.

How a Japanese labor firm is leveraging traditional osteopathy and high-profile sports events to execute an ambitious global expansion strategy.

Fate Therapeutics' latest data suggests its iPSC-derived CAR-T could revolutionize lupus care, moving cell therapy beyond cancer and into the mainstream.

A deepening corporate governance battle pits STAAR Surgical's board against its largest shareholder and all major proxy firms over a $1.5B Alcon deal.

EyeYon Medical's synthetic corneal implant, EndoArt, just got FDA approval for U.S. trials, offering a fix for the global donor tissue shortage.

ATI Inc. names operational veteran Rob Foster as its new CFO, signaling a strategic bet that manufacturing prowess is the key to financial success.

Newron launches a pivotal US trial for its novel schizophrenia drug, evenamide, aiming to help millions who don't respond to current treatments.

New data reveals Syndax's Revuforj is a game-changer for leukemia, sparking a battle for market dominance in targeted cancer therapy.

Monaghan Medical just won its 10th Zenith Award, voted on by clinicians. We unpack the strategy behind their decade of dominance in respiratory tech.

A new dermatology clinic opens in rural Vermont, a case study in corporate-backed expansion. But does this new model solve the access crisis for all?

How does a MedTech firm win 'Top Workplace' twice? Echosens proves that a mission-driven culture is the ultimate catalyst for innovation and market leadership.

AsymBio's massive Shanghai facility isn't just about capacity; it's a key move in the high-stakes world of advanced biologic drug production.

New data shows Ascentage Pharma's drug achieves responses where a leading therapy fails, signaling a strategic coup in the high-stakes oncology market.

A medical breakthrough dismantles a core barrier in cancer treatment, making stem cell transplants a reality for nearly everyone, regardless of ancestry.

Swedish innovator SciBase is overhauling its capital structure with a complex warrant buyback. Is this a strategic masterstroke or a necessary defensive play?

B. Braun's new ready-to-activate antibiotic system promises to save time, reduce errors, and streamline care. Here's how it could reshape hospital efficiency.

New long-term data suggests zorevunersen may modify Dravet syndrome, not just treat it. A look at the science, the strategy, and the stakes.

Lexicon's sotagliflozin may revolutionize HFpEF treatment by targeting adipose tissue, a move that could differentiate it in a crowded market.

A Japanese genomics leader is using AI and a massive local database to offer personalized cancer risk predictions, a move that could redefine preventative care.

A new Regina clinic uses high-tech chairs to fight a silent health epidemic, blending innovation with a mission to break the billion-dollar taboo of incontinence.